340 related articles for article (PubMed ID: 25550557)
1. Epidermal growth factor-induced cell death and radiosensitization in epidermal growth factor receptor-overexpressing cancer cell lines.
Kim K; Wu HG; Jeon SR
Anticancer Res; 2015 Jan; 35(1):245-53. PubMed ID: 25550557
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
[TBL] [Abstract][Full Text] [Related]
3. Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells.
Wu J; Zuo F; Du J; Wong PF; Qin H; Xu J
Mol Med Rep; 2013 Aug; 8(2):597-602. PubMed ID: 23807305
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
[TBL] [Abstract][Full Text] [Related]
5. FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
Ishitsuka A; Fujine E; Mizutani Y; Tawada C; Kanoh H; Banno Y; Seishima M
Int J Mol Med; 2014 Oct; 34(4):1169-74. PubMed ID: 25109763
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
Li P; Zhang Q; Torossian A; Li ZB; Xu WC; Lu B; Fu S
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e391-7. PubMed ID: 22414288
[TBL] [Abstract][Full Text] [Related]
7. Modulation of radiation response by histone deacetylase inhibition.
Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
[TBL] [Abstract][Full Text] [Related]
8. Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway.
Lee MS; Cha EY; Sul JY; Song IS; Kim JY
Phytother Res; 2011 Jun; 25(6):833-7. PubMed ID: 21089180
[TBL] [Abstract][Full Text] [Related]
9. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
10. Regulation by ceramide of epidermal growth factor signal transduction and mitogenesis in cell lines overexpressing the growth factor receptor.
Gallardo G; Tabraue C; Quintana J; López-Blanco F; Cabrera J; Díaz R; Estévez F; Ruiz de Galarreta CM; Fanjul LF; Santana P
Cell Mol Biol (Noisy-le-grand); 2000 Nov; 46(7):1305-12. PubMed ID: 11075960
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
12. Correlation of HER1/EGFR expression and degree of radiosensitizing effect of the HER1/EGFR-tyrosine kinase inhibitor erlotinib.
Kim JC; Ali MA; Nandi A; Mukhopadhyay P; Choy H; Cao C; Saha D
Indian J Biochem Biophys; 2005 Dec; 42(6):358-65. PubMed ID: 16955736
[TBL] [Abstract][Full Text] [Related]
13. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
14. Blockade of the epidermal growth factor receptor tyrosine kinase activity by quercetin and luteolin leads to growth inhibition and apoptosis of pancreatic tumor cells.
Lee LT; Huang YT; Hwang JJ; Lee PP; Ke FC; Nair MP; Kanadaswam C; Lee MT
Anticancer Res; 2002; 22(3):1615-27. PubMed ID: 12168845
[TBL] [Abstract][Full Text] [Related]
15. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells.
Lee DH; Szczepanski MJ; Lee YJ
J Cell Biochem; 2009 Apr; 106(6):1113-22. PubMed ID: 19229860
[TBL] [Abstract][Full Text] [Related]
16. Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells.
Fattah OM; Cloutier SM; Kündig C; Felber LM; Gygi CM; Jichlinski P; Leisinger HJ; Gauthier ER; Mach JP; Deperthes D
Int J Cancer; 2006 Nov; 119(10):2455-63. PubMed ID: 16858684
[TBL] [Abstract][Full Text] [Related]
17. The in vitro and in vivo anti-tumor effect of KO-202125, a sauristolactam derivative, as a novel epidermal growth factor receptor inhibitor in human breast cancer.
Oh M; Lee JY; Shin DH; Park JH; Oian T; Kim HJ; Cho SD; Oh SH; Min YK; Kong G
Cancer Sci; 2011 Mar; 102(3):597-604. PubMed ID: 21205071
[TBL] [Abstract][Full Text] [Related]
18. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
19. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Liu H; Li L; Li XQ; Liu XJ; Zhen YS
Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
[TBL] [Abstract][Full Text] [Related]
20. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
